Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer

Purpose We aimed to assess whether anti-EGFR combined chemotherapy regimens are related with loss of skeletal muscle mass and to compare cetuximab and panitumumab therapies in the aspect of skeletal muscle area change as well as to assess whether skeletal muscle mass loss has prognostic significance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical & translational oncology 2019-11, Vol.21 (11), p.1510-1517
Hauptverfasser:	Köstek, O., Demircan, N. C., Gökyer, A., Küçükarda, A., Sunal, B. S., Hacıoğlu, M. B., Eslame, H., Solak, S., Yılmaz, E., Uzunoğlu, S., Tunçbilek, N., Çiçin, İ., Erdoğan, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents, Immunological - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cetuximab - adverse effects Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology ErbB Receptors - antagonists & inhibitors Female Fluorouracil - administration & dosage Genes, ras Humans Leucovorin - administration & dosage Male Medicine Medicine & Public Health Middle Aged Muscle, Skeletal - diagnostic imaging Muscle, Skeletal - drug effects Muscular Atrophy - chemically induced Muscular Atrophy - diagnostic imaging Oncology Organoplatinum Compounds - administration & dosage Panitumumab - adverse effects Prognosis Research Article Retrospective Studies Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!